Do published ADA studies support the ADA-EASD position statement for the management of hyperglycaemia in type 2 diabetics?

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Rimareix F;Rimareix F; Bauduceau B
  • Source:
    Annales d'endocrinologie [Ann Endocrinol (Paris)] 2013 Jul; Vol. 74 (3), pp. 207-10. Date of Electronic Publication: 2013 Jun 06.
  • Publication Type:
    Comparative Study; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: France NLM ID: 0116744 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-3941 (Electronic) Linking ISSN: 00034266 NLM ISO Abbreviation: Ann Endocrinol (Paris) Subsets: MEDLINE
    • Publication Information:
      Publication: <1990- >: Paris : Elsevier
      Original Publication: Paris, Masson.
    • Subject Terms:
      Practice Guidelines as Topic*; Diabetes Mellitus, Type 2/*therapy ; Hyperglycemia/*therapy; Choice Behavior ; Consensus ; Decision Making ; Diabetes Mellitus, Type 2/complications ; Drug Therapy, Combination/methods ; Europe ; Humans ; Hyperglycemia/etiology ; Hypoglycemic Agents/therapeutic use ; Metformin/therapeutic use ; Risk Reduction Behavior ; Societies, Medical ; United States
    • Abstract:
      The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a position statement in 2012 on the management of hyperglycaemia in patients with type 2 diabetes. The Société Francophone du Diabète (SFD) adopted it while awaiting future French recommendations. This new care approach individualises the therapeutic choices and objectives for each patient based on their characteristics, through emphasis on the need for mutual cooperation with the patient in decision-making. Glycaemic management should naturally be considered in the context of overall cardiovascular risk reduction, which should remain the primary objective of treatment. The cornerstone of this treatment is based on lifestyle modifications, with the addition of metformin monotherapy if the desired glycaemic control is not attained. There are multiple second- and third-line treatment possibilities, and insulin therapy is an option that can be considered early in the bitherapy stage. On the whole, large published studies at the ADA conference in Philadelphia in June 2012, which are the subject of this article, support this patient-centred position statement.
      (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
    • Accession Number:
      0 (Hypoglycemic Agents)
      9100L32L2N (Metformin)
    • Publication Date:
      Date Created: 20130611 Date Completed: 20140411 Latest Revision: 20161031
    • Publication Date:
      20240628
    • Accession Number:
      10.1016/j.ando.2013.04.001
    • Accession Number:
      23747137